TELABio’s PRS Struggles and Recovery Plan | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20064584

Show notes

TELAs Bio’s Q2 earnings missed expectations, with revenue down 4% to $19.3M, largely due to a slump in their OviTex PRS line—blamed on slow new rep ramp-up and shaky sales strategy. Hospital bundling continues to hurt their competitive edge, echoing their ongoing legal battle with Becton Dickinson. Yet, their hernia products surged 12% in volume, and international growth remains strong. The PRS business, still navigating European regulatory hurdles, is getting renewed focus—with a revamped market access team, sales training, and cost restructuring underway. Full-year guidance has been pulled as they recalibrate. Despite the headwinds, leadership is bullish on H2, betting on PRS recovery and expanding hernia reach into complex cases. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/dbca62da3ea0a04d

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.